InflaRx N.V.
NASDAQ:IFRXBiotechnology
-$0.02 today
- Market cap
- $169.47M
- Beta
- 2.44
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$0.59
Volume 1.99M
Average 1.80M
IFRX Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
InflaRx N.V.NASDAQ: IFRX
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin not reported for Q1 FY2026
Context
- Net margin widened in 1 of the last 2 fiscal years.
- FY2025 was the lowest level in the 3 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 3 analysts of -109340.2% for the fiscal year ending Dec 2026, up from -155582.1% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- —— QoQ
- Last fiscal yearDec 2025
- -155582.1%-127797.1 pp YoY
- LTMMar 2026
- -146303.9%-111837.5 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | -127186.1 pp | — |
| 1 year | -127797.1 pp | +46241.8 pp | +174039.0 pp |
| 3 years | — | -54049.5 pp | — |
| 5 years | +155199.6 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -155582.1%
- Year-over-year change
- -127797.1pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -155582.1% | -127797.1pp |
| FY2024 | 2024-12-31 | -27785.0% | +39845.7pp |
| FY2023 | 2023-12-31 | -67630.7% | — |
| FY2022 | 2022-12-31 | — | — |
| FY2021 | 2021-12-31 | — | — |
Net Margin vs competitors
How IFRX compares with its peers on the latest reported figures
- IFRX's LTM Mar 2026 net margin of -146303.9% is the lowest of the 6 companies compared; the peer median is -5668.6%.
- Its year-over-year change of -111837.5 pp is the lowest of 5, against a peer median of -4039.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -154.2% | +214.9 pp | -10.6 pp | |
| LTM Mar 2026 | -4987.4% | -3454.4 pp | +10754.8 pp | |
IMAImageneBio Inc | FY2025 | -5668.6% | -4623.8 pp | -5228.3 pp |
| LTM Mar 2026 | -36857.4% | — | -38572.9 pp | |
| FY2025 | -86687.5% | -86627.5 pp | — | |
| LTM Mar 2026 | -146303.9% | -111837.5 pp | — | |
ARTVArtiva Biotherapeutics, Inc. | FY2025 | — | — | — |
KLRSKalaris Therapeutics Inc | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding IFRX) | -5668.6% | -4039.1 pp | -2619.4 pp | |
Competitors are the stored peer set for IFRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 63.09K | 165.79K | 29.33K |
| Cost of Revenue | 0 | 0 | 532.26K | 3.32M | 7.27M |
| Gross Profit | 0 | 0 | (469.17K) | (3.15M) | (7.24M) |
| Gross Margin | — | — | -743.7% | -1900.8% | -24677.9% |
| Research & Development | 35.7M | 37.53M | 41.02M | 35.36M | 25.72M |
| Selling, General & Admin | 11.43M | 14.34M | 16.12M | 19.33M | 17.56M |
| Operating Expenses | 47.63M | 32.24M | 44.13M | 49.75M | 41.02M |
| Depreciation & Amortization | 669.43K | 596.6K | 567.78K | 485.11K | 419.48K |
| EBITDA | (44.94M) | (28.84M) | (42.06M) | (45.55M) | (45.16M) |
| EBITDA Margin | — | — | -66674.3% | -27476.7% | -153976.3% |
| Operating Income | (47.63M) | (32.24M) | (44.59M) | (52.91M) | (48.26M) |
| Operating Margin | — | — | -70685.6% | -31911.4% | -164525.5% |
| Interest Income | 109.39K | 608.68K | 3.8M | 3.2M | 1.77M |
| Interest Expense | 24.77K | 45.25K | 35.63K | 20.66K | 37.69K |
| Other Income / Expenses | 2M | 2.75M | 1.93M | 6.85M | 2.64M |
| Income Before Tax | (45.63M) | (29.48M) | (42.67M) | (46.06M) | (45.62M) |
| Pre-Tax Margin | — | — | -67630.7% | -27781.8% | -155540.2% |
| Income Tax Expense | 0 | 0 | 0 | 5.22K | 12.28K |
| Net Income | (45.63M) | (29.48M) | (42.67M) | (46.06M) | (45.63M) |
| Net Margin | — | — | -67630.7% | -27785.0% | -155582.1% |
| EPS (Basic) | (1.10) | (0.61) | (0.78) | (0.78) | (0.66) |
| EPS (Diluted) | (1.10) | (0.61) | (0.78) | (0.78) | (0.66) |
| Weighted Avg Shares | 41.63M | 44.21M | 54.94M | 58.92M | 67.29M |
| Weighted Avg Shares (Diluted) | 41.63M | 44.21M | 54.94M | 58.92M | 67.29M |
InflaRx N.V.
NASDAQ:IFRX
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.